Un message du président de la SFTCG
Review written by Alessandro Aiuti, Giuliana Ferrari & Adrien Thrasher
New Horizons in the Management of ADA-SCID is a free educational resource for healthcare professionals managing patients with this rare disease.
To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines. The academic sector plays an important role in the development of innovative medicines. Their scientific research is often at the source of novel methodologies and innovative medicines with a potential to benefit patients with rare diseases.
San Sebastián, Spain, June 4, 2020 - VIVEbiotech, S.L., a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces a collaboration with Xyphos Biosciences for the development its CAR-T™ cell therapy for people with hematological cancer.